Trials / Terminated
TerminatedNCT03797261
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase 1b Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL)/diffuse large B-cell lymphoma (DLBCL). This study will include a dose escalation phase to identify the maximum tolerated dose/recommended phase 2 dose (MTD/RPTD) of venetoclax plus AMG 176 as well as a dose expansion phase to confirm safety, explore efficacy, and confirm the suitability of the preliminary RPTD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax | tablet, oral |
| DRUG | AMG 176 | solution, intravenous |
Timeline
- Start date
- 2019-03-18
- Primary completion
- 2019-12-30
- Completion
- 2019-12-30
- First posted
- 2019-01-09
- Last updated
- 2021-12-07
Locations
17 sites across 3 countries: United States, Australia, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03797261. Inclusion in this directory is not an endorsement.